Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05245006 · ClinicalTrials.gov registry record · Phase 1

PET Imaging Study of 89Zr-DFO-YS5 in Men With Prostate Cancer

A Phase 1 study of Prostate Cancer and Metastatic Castration-Resistant Prostate Cancer, sponsored by Robert Flavell, MD, PhD.

Active
Registry status
Phase 1
Development phase
30
Enrollment target
1
Study location

NCT05245006 is a Phase 1 study of Prostate Cancer and Metastatic Castration-Resistant Prostate Cancer that is active but no longer recruiting, run by Robert Flavell, MD, PhD. The registered enrollment target is 30 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05245006, a Phase 1 study of Prostate Cancer and Metastatic Castration-Resistant Prostate Cancer, is active but no longer recruiting, sponsored by Robert Flavell, MD, PhD.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

CD46 is an exciting new therapeutic target in prostate cancer, with the antibody drug conjugate FOR46 under investigation in phase I clinical trials. The hypothesis of the study is that CD46 expression, measured via our novel imaging biomarker, is a characteristic feature of mCRPC, and particularly common in the most lethal forms of the disease including adenocarcinoma and Small-cell neuroendocrine carcinoma (SCNC). These data will provide crucial information about the feasibility of targeting cluster of differentiation 46 (CD46) in mCRPC, will be used guide the development of novel therapeutic and theranostic agents, to help develop treatments that improve outcomes for men with the most lethal forms of prostate cancer.

Conditions Studied

Prostate Cancer Metastatic Castration-Resistant Prostate Cancer

Interventions

  • PROCEDURE Positron Emission Tomography (PET)/Computerized tomography (CT)
  • DRUG 89Zr-DFO-YS5
  • BIOLOGICAL YS5 antibody
  • PROCEDURE Positron Emission Tomography (PET)/Magnetic Resonance Imaging (MRI)

Study Locations (1)

California

  • University of California, San Francisco - San Francisco

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2022-03-18
Est. Completion 2027-07-31
Phase Phase 1

Sponsor

Robert Flavell, MD, PhD

5 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05245006

The ClinicalTrials.gov registry entry for NCT05245006 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (95% lower). The listed sponsor is Robert Flavell, MD, PhD, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 4 interventions - of which Positron Emission Tomography (PET)/Computerized tomography (CT) is the first listed.

NCT05245006 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT05245006 about?

NCT05245006 is a clinical study titled "PET Imaging Study of 89Zr-DFO-YS5 in Men With Prostate Cancer". CD46 is an exciting new therapeutic target in prostate cancer, with the antibody drug conjugate FOR46 under investigation in phase I clinical trials. The hypothesis of the study is that CD46 expression, measured via our novel imaging biomarker, is a characteristic feature of mCRPC, and particularly ...

What is the current status of trial NCT05245006?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2022-03-18. Estimated completion is 2027-07-31.

What conditions does trial NCT05245006 study?

This clinical trial studies the following conditions: Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer.

What interventions are being tested in trial NCT05245006?

The interventions under investigation include: Positron Emission Tomography (PET)/Computerized tomography (CT) (PROCEDURE), 89Zr-DFO-YS5 (DRUG), YS5 antibody (BIOLOGICAL), Positron Emission Tomography (PET)/Magnetic Resonance Imaging (MRI) (PROCEDURE).

Who is sponsoring clinical trial NCT05245006?

This trial is sponsored by Robert Flavell, MD, PhD, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05245006 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Prostate Cancer

All registered trials for this condition

Metastatic Castration-Resistant Prostate Cancer

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.